Actuate Therapeutics (ACTU) Stock Price, News & Analysis

Company Overview

Actuate Therapeutics, Inc., headquartered in Irvine, California, is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies targeting hormone-driven pathways and DNA damage repair mechanisms in oncology. The company leverages proprietary formulation technologies and deep scientific expertise to create treatments aimed at improving outcomes for patients with advanced cancers.

The company’s lead asset, onapristone extended release (ONA-XR), is an oral selective progesterone receptor antagonist designed to block progesterone-driven tumor growth. ONA-XR is being evaluated in multiple clinical trials, including studies in metastatic breast cancer and endometrial carcinoma. In addition to ONA-XR, Actuate is advancing a pipeline of earlier-stage programs that focus on modulating DNA damage response pathways, with the goal of addressing treatment resistance and enhancing precision therapy options.

Since its founding in 2016, Actuate Therapeutics has pursued strategic collaborations with academic institutions and clinical research sites across North America and Europe. The company’s management team, led by President and Chief Executive Officer Mark McCamish, Ph.D., brings together extensive experience in oncology drug development, regulatory strategy and commercialization planning. Actuate remains committed to translating scientific innovation into meaningful therapeutic advances for patients with high-unmet-need cancers.

Key Stats

• Today's Range: $6.00 to $7.33
• 50-Day Range: $5.82 to $11.36
• 52-Week Range: $5.50 to $11.99
• Volume: 618,575 shs
• Average Volume: 60,573 shs
• Market Capitalization: $120.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.50
• Consensus Rating: Buy

Actuate Therapeutics Stock Analysis - MarketRank™

Actuate Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 408th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Actuate Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Actuate Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Actuate Therapeutics has a P/B Ratio of 626.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ACTU.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Actuate Therapeutics does not currently pay a dividend.

Dividend Growth

Actuate Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for ACTU.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.94

News Sentiment

Actuate Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Actuate Therapeutics this week, compared to 1 article on an average week.

Search Interest

3 people have searched for ACTU on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

1 people have added Actuate Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Actuate Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,499,988.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

69.34% of the stock of Actuate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

ACTU Stock Analysis - Frequently Asked Questions

How have ACTU shares performed this year?

Actuate Therapeutics' stock was trading at $7.96 at the beginning of the year. Since then, ACTU stock has decreased by 21.4% and is now trading at $6.26.

How were Actuate Therapeutics' earnings last quarter?

Actuate Therapeutics, Inc. (NASDAQ:ACTU) released its quarterly earnings results on Thursday, May, 15th. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.06.

When did Actuate Therapeutics IPO?

Actuate Therapeutics (ACTU) raised $27 million in an initial public offering (IPO) on Tuesday, August 13th 2024. The company issued 3,000,000 shares at $8.00-$10.00 per share. Titan Partners acted as the underwriter for the IPO and Newbridge Securities Corp. was co-manager.

Who are Actuate Therapeutics' major shareholders?

Actuate Therapeutics' top institutional investors include Gleason Group Inc. (0.10%). Insiders that own company stock include Todd S Thomson, Leslie W Kreis, Equity Cof Lp Bios and Aaron GL Fletcher.
View institutional ownership trends.

How do I buy shares of Actuate Therapeutics?

Shares of ACTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Actuate Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Actuate Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Aileron Therapeutics (ALRN), Amgen (AMGN) and AstraZeneca (AZN).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACTU
• Previous Symbol: NASDAQ:ACTU
• CIK: 1652935
• Web: N/A
• Phone: (847) 986-4190
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Actuate Therapeutics: $20.50
• High Price Target: $21.00
• Low Price Target: $20.00
• Potential Upside/Downside: +227.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$27.28 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -339.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.46
• Quick Ratio: 0.46

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.01 per share
• Price / Book: 626.00

Miscellaneous

• Outstanding Shares: 19,620,000
• Free Float: 6,015,000
• Market Cap: $122.82 million
• Optionable: N/A
• Beta: N/A